Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.39B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.18M
Average 0.08M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Nanobiotix S.A.
NASDAQ:NBTX
Intrinsic Alpha fair value
Locked
Current Price
$27.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +83.8% | +37.6% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +83.8% over three years. Forward estimates point to Revenue at +37.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
ImmunityBio, Inc. NASDAQ:IBRX | $6.40B | $6.02 | Not rated | -8.6 | +225.25% |
Tyra Biosciences, Inc. NASDAQ:TYRA | $1.38B | $20.03 | Not rated | -13.4 | -6.05% |
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | $850.77M | $9.45 | Not rated | -6.8 | -46.45% |
Kura Oncology, Inc. NASDAQ:KURA | $713.90M | $7.77 | Not rated | -2.9 | -33.06% |
Nuvectis Pharma, Inc. NASDAQ:NVCT | $696.03M | $20.24 | Not rated | -11.2 | +237.41% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -43.87% |
Immix Biopharma, Inc. NASDAQ:IMMX | $649.96M | $7.84 | Not rated | -10.1 | +75.12% |
Candel Therapeutics, Inc. NASDAQ:CADL | $474.42M | $6.20 | Not rated | -9.2 | +16.06% |
Puma Biotechnology, Inc. NASDAQ:PBYI | $401.70M | $7.77 | Overvalued | 15.4 | +47.11% |
Black Diamond Therapeutics, Inc. NASDAQ:BDTX | $84.48M | $1.47 | Overvalued | -2.2 | -63.52% |
Continue the stock analysis
Jump to another research area for this company.